TMCnet News
Evelo Biosciences to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. EST on Thursday, February 13, 2020 to report its fourth quarter and full year 2019 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 5849487. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call. About Evelo Biosciences Evelo currently has four product candidates: EDP1815, EDP1066, and EDP1867 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas. For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn. Contact |